pomalidomide has been researched along with cnf 2024 in 1 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (cnf 2024) | Trials (cnf 2024) | Recent Studies (post-2010) (cnf 2024) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 28 | 0 | 23 |
| Protein | Taxonomy | pomalidomide (IC50) | cnf 2024 (IC50) |
|---|---|---|---|
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | 0.0394 | |
| Heat shock protein HSP 90-beta | Homo sapiens (human) | 0.0464 | |
| Endoplasmin | Canis lupus familiaris (dog) | 0.124 | |
| Heat shock protein 75 kDa, mitochondrial | Homo sapiens (human) | 0.3125 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Y; Huang, X; Jiang, Q; Li, G; Lin, S; Liu, J; Liu, Q; Liu, Y; Tang, Y; Tu, G; Wu, L; Wu, X; Xu, J; Yu, Z | 1 |
1 other study(ies) available for pomalidomide and cnf 2024
| Article | Year |
|---|---|
Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; HSP90 Heat-Shock Proteins; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Molecular Structure; Proteolysis; Structure-Activity Relationship; Tumor Cells, Cultured | 2022 |